Showing results (11-20 of 28) with videos related to
Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|April 17, 2002
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignanciesArno J Mundt, Anthony E Lujan, Jacob Rotmensch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2003
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology GroupDavid H Moore, James Donnelly, William P McGuire, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupDavid S Miller, John A Blessing, Carolyn N Krasner, et al.International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patientsMaryann Schroder, Loren K Mell, Jean A Hurteau, et al.Obstetrics and Gynecology|December 22, 2010
Lifestyle challenges in endometrial cancer survivorshipVivian E von Gruenigen, Steven E Waggoner, Heidi E Frasure, et al.Gynecologic Oncology|October 15, 2023
Safety and efficacy of topical artesunate for the treatment of vulvar intraepithelial neoplasia 2/3Chad M Michener, Stephanie Ricci, Mariam AlHilli, et al.Frontiers in Oncology|June 23, 2015
Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic CancerCharles A Kunos, Tracy M Sherertz, Mazen Mislmani, et al.Anti-Cancer Drugs|May 5, 2012
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I studyVivian E von Gruenigen, Heidi E Frasure, Deborah A Smith, et al.Gynecologic Oncology|November 16, 2010
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology GroupCharles A Kunos, Michael W Sill, Thomas E Buekers, et al.Gynecologic Oncology|May 11, 2015
A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group studyD Scott McMeekin, Michael W Sill, Joan L Walker, et al.Pageof 3